Table 2:
Clinical outcomes of patients in the Canadian Treatments for COVID-19 trial
| Outcome | No. (%)* of patients receiving remdesivir n = 634 |
No. (%)* of patients receiving standard of care n = 647 |
RR (95% CI) or difference in means/medians (95% CI) | Risk difference, % (95% CI) |
|---|---|---|---|---|
| In-hospital mortality, n = 1267† | 117 (18.7) | 145 (22.6) | 0.83 (0.67 to 1.03) | −3.9 (−8.3 to 1.03) |
| Mortality by 60 d, n = 1052‡ | 127 (24.8) | 152 (28.2) | 0.88 (0.72 to 1.07) | −3.4 (−8.8 to 1.9) |
| Need for new mechanical ventilation, n = 1168§ | 46 (8.0) | 89 (15.0) | 0.53 (0.38 to 0.75) | −7.0 (−10.6 to −3.4) |
| Duration of hospital stay† median (IQR) | 10 (6 to 18) | 9 (6 to 17) | 0 (−1 to 0) | |
| Duration of hospital stay for survivors, median (IQR); n = 1005 | 9 (6 to 17) | 9 (6 to 16) | 0 (−1 to 0) | |
| Duration of hospital stay for nonsurvivors, median (IQR); n = 262 | 12 (5 to 20) | 11 (6 to 20) | 0 (−2 to 2) | |
| Need for new oxygen,¶ n = 125 | 16 (22.5) | 16 (29.6) | 0.76 (0.42 to 1.38) | −7.1 (−2.3 to 8.5) |
| Oxygen-free days at day 28, mean ± SD,** median (IQR); n = 1168 | 15.9 ± 10.5 20 (0 to 24) |
14.2 ± 11.1 19 (0 to 24) |
1.7 (0.4 to 3.0) 0 (−1 to 0) |
|
| Ventilator-free days at day 28, mean ± SD,** median (IQR); n = 1168 | 21.4 ± 11.3 28 (19 to 28) |
19.5 ± 12.3 28 (1 to 28) |
1.9 (0.5 to 3.2) 0 (0) |
|
| Safety | ||||
| New hepatic dysfunction†† | 82 (13.1) | 88 (13.7) | 0.96 (0.72 to 1.26) | −0.6 (−4.4 to 3.1) |
| New dialysis‡‡; n = 1265 | 16 (2.6) | 15 (2.3) | 1.09 (0.54 to 2.19) | 0.2 (−1.5 to 1.9) |
| Day 5 serum creatinine, mean ± SD; median (IQR); n = 936 | 86.7 ± 78.0 71 (57–88.5) |
87.7 ± 79.2 69 (57–87.5) |
−0.92 (−10.9 to 9.1) −1 (−4 to 2) |
|
Note: ALT = alanine aminotransferase, CI = confidence interval, IQR = interquartile range, RR = relative risk, SD = standard deviation.
Unless otherwise specified.
15 patients have missing hospital mortality and length of stay: 6 patients still in hospital and 9 withdrew consent.
230 patients withdrew consent or were lost to follow-up postdischarge.
Defined as being on invasive ventilation on day 2 onward but not on day 1.
Defined as being on oxygen on day 2 and no oxygen therapy on day 1.
Patients who were transferred to other facility or received palliative care before day 28 and patients who were readmitted and coded as oxygen at day 29 were considered as missing.
Defined as acute liver function, as clinically determined, or ALT at day 5 > twice ALT at day 1.
Defined as dialysis for those who were not on dialysis at baseline. Sixteen patients were on dialysis on day 1 and were excluded from the denominator, n = 1265: 625 remdesivir and 640 control.